Vertex Pharmaceuticals Unrecognized Tax Benefits Current Period Increases remained flat by 0.0% to $29.88M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 0.3%, from $29.80M to $29.88M. Over 2 years (FY 2023 to FY 2025), Unrecognized Tax Benefits Current Period Increases shows relatively stable performance with a 1.5% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase suggests higher tax uncertainty or a more aggressive approach to tax planning.
This metric tracks the increase in unrecognized tax benefits resulting from tax positions taken during the current repor...
Standard disclosure in the 'Uncertain Tax Positions' section of tax footnotes.
is_adi_unrecognized_tax_benefits_current_period_increases| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $116.00M | $119.20M | $119.50M |
| YoY Change | — | +2.8% | +0.3% |
We use cookies for analytics. See our Privacy and Cookie Policy.